Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501-Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2011
This article has no abstract
Epistemonikos ID: 1aec3dc58780ab34651bb779250ee9b6f10dde5f
First added on: Feb 04, 2025